Cure My Disease

Don't miss your cure!

 Log in / Sign up

Baltimore study enlists peers to fight HIV and overdose among drug users

NCT ID NCT05320835

Prevention Sponsor: Johns Hopkins Bloomberg School of Public Health Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tests whether a peer-driven program can help people who inject drugs in Baltimore reduce their risk of HIV, hepatitis C, and overdose. Researchers will identify high-risk injection settings and train peers to promote safer practices, like carrying naloxone and avoiding shared cookers. The study enrolls 285 current opioid users and tracks changes in prevention behaviors over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
peer-driven behavioral intervention
What this could lead to
If successful, this could point toward a scalable community-based strategy to reduce HIV, hepatitis C, and overdose in high-risk populations.
What could go wrong
This is a small pilot study (285 participants) in one city, so results may not apply elsewhere. The intervention relies on peer networks, which may be hard to sustain or replicate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 285 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2022

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Current drug user (opioid use in the prior two weeks) Exclusion Criteria: * Any mental or physical health impairment that impedes ability to participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug overdose are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Drug Overdose opiate dependence hepatitis C virus infection prevention target HIV infectious disease prevention target poisoning prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Drug overdose HCV HIV infections

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Lighthouse Studies at Peer Point

    RECRUITING

    Baltimore, Maryland, 21205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.